Glenmark Pharmaceuticals' - Glenmark Generics Incorporation, USA, (GGI) the US subsidiary of Glenmark Generics has been granted tentative approval from United States Food and Drug Administration (USFDA) for Montelukast Sodium 10 mg tablets, their generic version of Singulair tablets by Merck.
IMS Health has recorded sales of Singulair 10 mg tablets for the 12 month period ending September 2011, as $3.2 billion. Based on the tentative approval for Montelukast Sodium tablets, Glenmark Generics should be able to launch the product upon patent expiry in August 2012.
Singulair is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older, for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older, for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older.
Glenmark's current portfolio consists of 73 products authorized for distribution in the US marketplace. The company has over 40 ANDA's pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
Glenmark Generics (GGL) is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.
Glenmark Pharmaceuticals, a leader among the emerging market companies in drug discovery and development and most of its active substances in the pipeline are first-in-Class. Glenmark’s achievements over the year include a major deal with Sanofi in Crohn's disease, completing Phase II trials of its first novel product, crofelemer and demonstrated higher sales and profit growth.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1854.15 |
| Dr. Reddys Lab | 1350.75 |
| Cipla | 1497.80 |
| Lupin | 2357.65 |
| Zydus Lifesciences | 1001.20 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
